Abstract
Giant-cell tumor (GCT) is a type of bone tumor that is usually benign. In this study, we investigate the clinicopathological features of GCT and identify unreported characteristics of such disease in Iranian patients. In this study, 50 GCT patients had been treated at a referral orthopedic hospital from March 2003 through March 2013. The patients’ sex, age, location of tumor, presenting symptoms, treatment methods, and recurrence rate were determined. To confirm the reliability of the initial diagnosis, hematoxylin and eosin (H-E) staining and P63 immunostaining were used. In this sample, 52 % of patients were male and 48 % were female. Among these patients, the most common symptom was pain. The most frequent surgical technique used for this group was the curettage, graft, and en bloc method. The lowest rate of tumor recurrence was observed in this technique. With the p63 immunostaining method, 27 cases were weakly positive and 14 cases were positive, while 9 cases were highly positive with episodes of recurrence. Of all body parts, GCT most commonly affects the knee. In our patients, the recurrence rate was 16 %, and all episodes of recurrence were observed in highly positive p63 patients. In summary, p63 could be a useful biomarker for the prognostication and assessment of GCT invasion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Algawahmed H, Turcotte R, Farrokhyar F, Ghert M (2010) High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis. Sarcoma 2010:586090
Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J, Gosheger G (2008) Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134:969–978
Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS (1999) Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 81:811–820
Dickson BC, Li SQ, Wunder JS, Ferguson PC, Eslami B, Werier JA (2008) Giant cell tumor of bone express p63. Mod Pathol 21:369–375
Errani C, Ruggieri P (2010) Marco Antonio Nogales Asenzio, Toscano A, Colangeli S, Rimondi E, Rossi G, Longhi A, Mercuri M. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 36(1):1–7
Kim Y, Nizami S, Goto H, Lee FY (2012) Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor. Clin Orthop Surg 4(2):107–116
Knochentumoren A, Becker WT (2008) Dohle J, Bernd L, Braun A, Cserhati M, Enderle A, Hovy L, Matejovsky Z, Szendroi M, Trieb K, Tunn PU. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 90:1060–1067
Komiya S, Inoue A (1993) Cementation in the treatment of giant cell tumor. Arch Orthop Trauma Surg 112:51–55
Labs K, Perka C, Schmidt GR (2001) Treatment of stages 2 and 3 giant-cell tumor. Arch Orthop Traum Surg 121:83–86
Lackman RD, Crawford EA, King JJ, Ogilvie CM (2009) Conservative treatment of Campanacci grade III proximal humerus giant cell tumors. Clin Orthop Relat Res 467(5):1355–1359
Lackman RD, Hosalkar HS, Ogilvie CM, Torbert JT, Fox EJ (2005) Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res 438:123–127
Lausten GS, Jensen PK, Schiodt T, Lund B (1996) Local recurrences in giant cell tumour of bone: long-term follow up of 31 cases. Int Orthop 20:172–176
Lee CH, Espinosa I, Jenson KC, Subramanian S, Zhu SX, Varma S (2008) Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol 21:531–539
Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP (2006) Giant cell tumor of bone. Am J Clin Oncol 29(1):96–99
Murphey MD, Nomikos GC, Flemming DJ, Gannon FH, Temple HT, Kransdorf MJ (2001) Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. RadioGraphics 21:1283–1309
Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ (2005) Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res 435:211–218
Richardson MJ, Dickinson K (1998) Giant cell tumor of bone. Bull Hosp Jt Dis 57:6–10
Solooki S, Vosoughi AR, Masoomi V (2011) Epidemiology of musculoskeletal tumors in Shiraz, south of Iran. Indian J Med Paediatr Oncol 32(4):187–191
Stacy GS, Peabody TD, Dixon LB (2003) Mimics on radiography of giant cell tumor of bone. AJR Am J Roentgenol 181(6):1583–1589
Turcotte RE (2006) Giant cell tumor of bone. Orthop Clin North Am 37(1):35–51
Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM et al (2002) Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 397:248–258
Unni KK, Inwards CY (2009) Dahlin’s bone tumors: general aspects and data on 10,165 cases. Lippincott Williams & Wilkins, Philadelphia, PA
Wang HC, Chien SH, Lin GT (2005) Management of grade III giant cell tumors of bones. J Surg Oncol 92(1):46–51
Wulling M, Engels C, Jesse N, Werner M, Delling G, Kaiser E (2001) The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 127(8):467–474
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vahid-Farahmandi, M., Abbasian, M. & Samani, S. Correlation between p63 expression and clinical behavior of giant-cell tumor of bone. Comp Clin Pathol 24, 827–830 (2015). https://doi.org/10.1007/s00580-014-1989-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00580-014-1989-4